Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2016 - 2026)

Gyre Therapeutics has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$1.7 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 1640.4% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 58.4% year-over-year, with the annual reading at $5.0 million for FY2025, 58.4% down from the prior year.
  • Net Income towards Common Stockholders was -$1.7 million for Q4 2025 at Gyre Therapeutics, down from $3.6 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is $171500.0 (2024), against an average of -$8.1 million.
  • Year-over-year, Net Income towards Common Stockholders skyrocketed 359.09% in 2022 and then tumbled 1640.4% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$20.4 million in 2021, then tumbled by 46.71% to -$29.9 million in 2022, then tumbled by 237.7% to -$101.0 million in 2023, then skyrocketed by 99.9% to -$99000.0 in 2024, then tumbled by 1640.4% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Income towards Common Stockholders are -$1.7 million (Q4 2025), $3.6 million (Q3 2025), and $442000.0 (Q2 2025).